N van der Maas1, J Dijs-Elsinga2, J Kemmeren1, A van Lier1, M Knol1, H de Melker1. 1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. 2. The Netherlands Perinatal Registry, Utrecht, the Netherlands.
Abstract
OBJECTIVE: This study aims to assess the safety of Influenza A(H1N1), vaccination administered during the second and third trimester and containing MF59 and thiomersal (Focetria(®) ), measured by pregnancy outcomes and infant's health. DESIGN: Cross-sectional linkage study. SETTING AND SAMPLE: A sample of pregnant women, eligible for prenatal screening, were invited to participate. METHODS: Questionnaire data were linked with the Netherlands Perinatal Registry (n = 1920). Information on infant growth, development (n = 1739) and infection-related contacts with the general practitioner (GP) during the first year of life (n = 1671) was obtained. MAIN OUTCOME MEASURES: Multivariate logistic regression was used to assess the association between H1N1 vaccination and small-for-gestational-age infant, preterm delivery and a composite adverse outcome, i.e. low Apgar-score, neonatal intensive care unit admission, neonatal resuscitation or perinatal death. Influence of maternal vaccination on growth, development and GP infection-related contact rates were assessed using multivariate linear mixed modelling and multivariate negative binomial regression, respectively. RESULTS: Response rate was 21%. Though we found differences in characteristics between unvaccinated and vaccinated women, in the multivariate analyses no association was found between H1N1 vaccination and small-for-gestational-age (odds ratio [OR] 0.84; 95% confidence interval [95% CI] 0.50-1.43), preterm delivery (OR 0.98; 95% CI 0.59-1.62) and the composite adverse outcome (OR 0.84; 95% CI 0.44-1.60). We found no differences in weight-for-age (-0.05; 95% CI -0.13 to 0.04), length-for-age (-0.01; 95% CI -0.09 to 0.06), head-circumference-for-age (-0.05; 95% CI -0.13 to 0.03), developmental scores (-0.06; 95% CI -0.28 to 0.17) and infection-related GP contact rates (incidence rate ratio 1.07; 95% CI 0.91-1.28) between infants of unvaccinated and vaccinated mothers. CONCLUSION: Pregnancy outcomes did not differ between H1N1-vaccinated and unvaccinated women. Furthermore, growth, development and GP infection-related contact rates, assessed after the first year of life, were similar in offspring of vaccinated and unvaccinated mothers. TWEETABLE ABSTRACT: No increased risk for adverse pregnancy outcomes and infant's health following influenza vaccination.
OBJECTIVE: This study aims to assess the safety of Influenza A(H1N1), vaccination administered during the second and third trimester and containing MF59 and thiomersal (Focetria(®) ), measured by pregnancy outcomes and infant's health. DESIGN: Cross-sectional linkage study. SETTING AND SAMPLE: A sample of pregnant women, eligible for prenatal screening, were invited to participate. METHODS: Questionnaire data were linked with the Netherlands Perinatal Registry (n = 1920). Information on infant growth, development (n = 1739) and infection-related contacts with the general practitioner (GP) during the first year of life (n = 1671) was obtained. MAIN OUTCOME MEASURES: Multivariate logistic regression was used to assess the association between H1N1 vaccination and small-for-gestational-age infant, preterm delivery and a composite adverse outcome, i.e. low Apgar-score, neonatal intensive care unit admission, neonatal resuscitation or perinatal death. Influence of maternal vaccination on growth, development and GP infection-related contact rates were assessed using multivariate linear mixed modelling and multivariate negative binomial regression, respectively. RESULTS: Response rate was 21%. Though we found differences in characteristics between unvaccinated and vaccinated women, in the multivariate analyses no association was found between H1N1 vaccination and small-for-gestational-age (odds ratio [OR] 0.84; 95% confidence interval [95% CI] 0.50-1.43), preterm delivery (OR 0.98; 95% CI 0.59-1.62) and the composite adverse outcome (OR 0.84; 95% CI 0.44-1.60). We found no differences in weight-for-age (-0.05; 95% CI -0.13 to 0.04), length-for-age (-0.01; 95% CI -0.09 to 0.06), head-circumference-for-age (-0.05; 95% CI -0.13 to 0.03), developmental scores (-0.06; 95% CI -0.28 to 0.17) and infection-related GP contact rates (incidence rate ratio 1.07; 95% CI 0.91-1.28) between infants of unvaccinated and vaccinated mothers. CONCLUSION: Pregnancy outcomes did not differ between H1N1-vaccinated and unvaccinated women. Furthermore, growth, development and GP infection-related contact rates, assessed after the first year of life, were similar in offspring of vaccinated and unvaccinated mothers. TWEETABLE ABSTRACT: No increased risk for adverse pregnancy outcomes and infant's health following influenza vaccination.
Authors: Azar Mehrabadi; Linda Dodds; Noni E MacDonald; Karina A Top; Eric I Benchimol; Jeffrey C Kwong; Justin R Ortiz; Ann E Sprague; Laura K Walsh; Kumanan Wilson; Deshayne B Fell Journal: JAMA Date: 2021-06-08 Impact factor: 56.272
Authors: Hassen Mohammed; Claire T Roberts; Luke E Grzeskowiak; Lynne C Giles; Gustaaf A Dekker; Helen S Marshall Journal: EClinicalMedicine Date: 2020-09-09
Authors: Deshayne B Fell; Kumanan Wilson; Robin Ducharme; Steven Hawken; Ann E Sprague; Jeffrey C Kwong; Graeme Smith; Shi Wu Wen; Mark C Walker Journal: PLoS One Date: 2016-08-03 Impact factor: 3.240
Authors: Jonas F Ludvigsson; Peter Ström; Cecilia Lundholm; Sven Cnattingius; Anders Ekbom; Åke Örtqvist; Nils Feltelius; Fredrik Granath; Olof Stephansson Journal: BMJ Date: 2015-11-16
Authors: Elizabeth P Schlaudecker; Flor M Munoz; Azucena Bardají; Nansi S Boghossian; Asma Khalil; Hatem Mousa; Mirjana Nesin; Muhammad Imran Nisar; Vitali Pool; Hans M L Spiegel; Milagritos D Tapia; Sonali Kochhar; Steven Black Journal: Vaccine Date: 2017-12-04 Impact factor: 3.641